![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GOT2 |
Gene summary for GOT2 |
![]() |
Gene information | Species | Human | Gene symbol | GOT2 | Gene ID | 2806 |
Gene name | glutamic-oxaloacetic transaminase 2 | |
Gene Alias | DEE82 | |
Cytomap | 16q21 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P00505 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2806 | GOT2 | HTA11_347_2000001011 | Human | Colorectum | AD | 6.61e-05 | 3.08e-01 | -0.1954 |
2806 | GOT2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.45e-08 | 5.73e-01 | -0.059 |
2806 | GOT2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 4.28e-07 | 6.51e-01 | 0.281 |
2806 | GOT2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.74e-11 | 5.42e-01 | 0.3859 |
2806 | GOT2 | A015-C-203 | Human | Colorectum | FAP | 4.51e-08 | -1.69e-01 | -0.1294 |
2806 | GOT2 | A002-C-201 | Human | Colorectum | FAP | 2.29e-02 | -1.41e-01 | 0.0324 |
2806 | GOT2 | A001-C-108 | Human | Colorectum | FAP | 6.70e-05 | -1.59e-01 | -0.0272 |
2806 | GOT2 | A002-C-205 | Human | Colorectum | FAP | 6.99e-05 | -2.05e-01 | -0.1236 |
2806 | GOT2 | A015-C-006 | Human | Colorectum | FAP | 6.81e-03 | -1.96e-01 | -0.0994 |
2806 | GOT2 | A002-C-114 | Human | Colorectum | FAP | 3.04e-03 | -1.85e-01 | -0.1561 |
2806 | GOT2 | A015-C-104 | Human | Colorectum | FAP | 1.20e-10 | -2.24e-01 | -0.1899 |
2806 | GOT2 | A002-C-016 | Human | Colorectum | FAP | 2.21e-03 | -1.76e-01 | 0.0521 |
2806 | GOT2 | A001-C-203 | Human | Colorectum | FAP | 1.33e-02 | -1.76e-01 | -0.0481 |
2806 | GOT2 | A002-C-116 | Human | Colorectum | FAP | 6.63e-07 | -1.79e-01 | -0.0452 |
2806 | GOT2 | A018-E-020 | Human | Colorectum | FAP | 6.69e-05 | -2.21e-01 | -0.2034 |
2806 | GOT2 | F034 | Human | Colorectum | FAP | 4.49e-04 | -1.84e-01 | -0.0665 |
2806 | GOT2 | F072B | Human | Colorectum | FAP | 1.71e-06 | -1.99e-01 | 0.257 |
2806 | GOT2 | LZE2T | Human | Esophagus | ESCC | 2.42e-04 | 9.84e-01 | 0.082 |
2806 | GOT2 | LZE4T | Human | Esophagus | ESCC | 4.31e-20 | 5.93e-01 | 0.0811 |
2806 | GOT2 | LZE7T | Human | Esophagus | ESCC | 1.44e-10 | 9.13e-01 | 0.0667 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000865212 | Thyroid | ATC | cellular amino acid biosynthetic process | 39/6293 | 76/18723 | 1.07e-03 | 5.63e-03 | 39 |
GO:190160712 | Thyroid | ATC | alpha-amino acid biosynthetic process | 35/6293 | 68/18723 | 1.76e-03 | 8.71e-03 | 35 |
GO:000657522 | Thyroid | ATC | cellular modified amino acid metabolic process | 82/6293 | 188/18723 | 2.60e-03 | 1.20e-02 | 82 |
GO:003087917 | Thyroid | ATC | mammary gland development | 62/6293 | 137/18723 | 2.96e-03 | 1.34e-02 | 62 |
GO:001482313 | Thyroid | ATC | response to activity | 37/6293 | 76/18723 | 4.57e-03 | 1.89e-02 | 37 |
GO:000756517 | Thyroid | ATC | female pregnancy | 82/6293 | 193/18723 | 6.04e-03 | 2.42e-02 | 82 |
GO:0050878112 | Thyroid | ATC | regulation of body fluid levels | 149/6293 | 379/18723 | 1.08e-02 | 3.90e-02 | 149 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa01200 | Colorectum | AD | Carbon metabolism | 55/2092 | 115/8465 | 5.53e-08 | 8.42e-07 | 5.37e-07 | 55 |
hsa00330 | Colorectum | AD | Arginine and proline metabolism | 23/2092 | 50/8465 | 8.27e-04 | 5.90e-03 | 3.76e-03 | 23 |
hsa01230 | Colorectum | AD | Biosynthesis of amino acids | 28/2092 | 75/8465 | 9.99e-03 | 3.89e-02 | 2.48e-02 | 28 |
hsa012001 | Colorectum | AD | Carbon metabolism | 55/2092 | 115/8465 | 5.53e-08 | 8.42e-07 | 5.37e-07 | 55 |
hsa003301 | Colorectum | AD | Arginine and proline metabolism | 23/2092 | 50/8465 | 8.27e-04 | 5.90e-03 | 3.76e-03 | 23 |
hsa012301 | Colorectum | AD | Biosynthesis of amino acids | 28/2092 | 75/8465 | 9.99e-03 | 3.89e-02 | 2.48e-02 | 28 |
hsa012004 | Colorectum | MSS | Carbon metabolism | 43/1875 | 115/8465 | 1.37e-04 | 1.17e-03 | 7.19e-04 | 43 |
hsa003304 | Colorectum | MSS | Arginine and proline metabolism | 23/1875 | 50/8465 | 1.52e-04 | 1.24e-03 | 7.61e-04 | 23 |
hsa012005 | Colorectum | MSS | Carbon metabolism | 43/1875 | 115/8465 | 1.37e-04 | 1.17e-03 | 7.19e-04 | 43 |
hsa003305 | Colorectum | MSS | Arginine and proline metabolism | 23/1875 | 50/8465 | 1.52e-04 | 1.24e-03 | 7.61e-04 | 23 |
hsa012006 | Colorectum | FAP | Carbon metabolism | 38/1404 | 115/8465 | 1.04e-05 | 1.44e-04 | 8.76e-05 | 38 |
hsa003306 | Colorectum | FAP | Arginine and proline metabolism | 16/1404 | 50/8465 | 5.33e-03 | 2.10e-02 | 1.27e-02 | 16 |
hsa012007 | Colorectum | FAP | Carbon metabolism | 38/1404 | 115/8465 | 1.04e-05 | 1.44e-04 | 8.76e-05 | 38 |
hsa003307 | Colorectum | FAP | Arginine and proline metabolism | 16/1404 | 50/8465 | 5.33e-03 | 2.10e-02 | 1.27e-02 | 16 |
hsa0120023 | Esophagus | ESCC | Carbon metabolism | 79/4205 | 115/8465 | 2.50e-05 | 1.21e-04 | 6.22e-05 | 79 |
hsa0123023 | Esophagus | ESCC | Biosynthesis of amino acids | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
hsa0120033 | Esophagus | ESCC | Carbon metabolism | 79/4205 | 115/8465 | 2.50e-05 | 1.21e-04 | 6.22e-05 | 79 |
hsa0123033 | Esophagus | ESCC | Biosynthesis of amino acids | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
hsa0120041 | Liver | HCC | Carbon metabolism | 89/4020 | 115/8465 | 3.92e-11 | 6.56e-10 | 3.65e-10 | 89 |
hsa0123021 | Liver | HCC | Biosynthesis of amino acids | 53/4020 | 75/8465 | 3.79e-05 | 2.11e-04 | 1.18e-04 | 53 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GOT2 | SNV | Missense_Mutation | novel | c.1213G>C | p.Asp405His | p.D405H | P00505 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-OL-A5RZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
GOT2 | insertion | Frame_Shift_Ins | novel | c.553_554insGGCTTAATTTGGCAATGTCTCAACAGAGAGTC | p.Lys185ArgfsTer56 | p.K185Rfs*56 | P00505 | protein_coding | TCGA-BH-A0GZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | ||
GOT2 | SNV | Missense_Mutation | c.469C>G | p.Leu157Val | p.L157V | P00505 | protein_coding | tolerated(0.25) | benign(0.029) | TCGA-C5-A1BK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
GOT2 | SNV | Missense_Mutation | novel | c.104A>G | p.His35Arg | p.H35R | P00505 | protein_coding | tolerated(0.16) | benign(0) | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
GOT2 | SNV | Missense_Mutation | rs754471368 | c.719N>T | p.Ala240Val | p.A240V | P00505 | protein_coding | tolerated(0.25) | benign(0.011) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
GOT2 | SNV | Missense_Mutation | c.986C>T | p.Ala329Val | p.A329V | P00505 | protein_coding | tolerated(0.08) | benign(0.005) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
GOT2 | SNV | Missense_Mutation | novel | c.889G>A | p.Asp297Asn | p.D297N | P00505 | protein_coding | tolerated(0.13) | benign(0.018) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
GOT2 | SNV | Missense_Mutation | c.273T>A | p.Asn91Lys | p.N91K | P00505 | protein_coding | tolerated(0.82) | benign(0.007) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GOT2 | SNV | Missense_Mutation | novel | c.281N>G | p.Lys94Arg | p.K94R | P00505 | protein_coding | deleterious(0.03) | possibly_damaging(0.858) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD |
GOT2 | SNV | Missense_Mutation | novel | c.712N>A | p.Leu238Ile | p.L238I | P00505 | protein_coding | tolerated(0.25) | possibly_damaging(0.611) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |